Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will release its first quarter 2020 financial results and operational highlights on May 14, 2020, at 7:05 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will release its first quarter 2020 financial results and operational highlights on May 14, 2020, at 7:05 AM ET. The company specializes in developing branded and generic topical drugs for skin diseases, utilizing proprietary microencapsulation technology for products such as Twyneo for acne and Epsolay for rosacea. Sol-Gel's pipeline includes early-stage treatments like SGT-210 for keratoderma and preclinical assets tapinarof and roflumilast.
Positive
- Utilizes proprietary microencapsulation technology for product development.
- Product pipeline includes promising treatments for various skin diseases.
Negative
- None.
Details
News Market Reaction – SLGL
The recorded move for SLGL in the trading session of this news was -1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report its first quarter 2020 financial results and operational highlights on Thursday, May 14, 2020 at 7:05 AM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Chiara Russo
Solebury Trout
+1-617-221-9197
crusso@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.